Abiomed provides on-site, on-call and online clinical support to help health care professionals achieve the best possible outcome for the patient.

Abiomed is a leading provider of groundbreaking medical technology that provides circulatory and oxygenation support. The Impella® heart pump platform is designed to enable the heart to rest and recover by improving blood flow and/or temporarily assisting with …

Learn more about how the FDA-approved Impella, the world's smallest heart pump, is safe, effective and supports your heart during a procedure. Hear the stories of patients and explore the latest innovations in Impella technology.

Abiomed was founded in 1981 for the purpose of developing the world's first artificial heart. This interactive timeline shows how Abiomed’s mission evolved to focus on native heart recovery. Through its history, Abiomed has been dedicated to bringing the most advanced and innovative technology to patients and physicians.

2022年12月22日 · Johnson & Johnson (NYSE: JNJ), the world’s largest, most diversified healthcare products company, today announced it has completed its acquisition of Abiomed, Inc. Abiomed is now part of Johnson & Johnson and will operate as a standalone business within Johnson & Johnson’s MedTech segment.

Abiomed provides collaborative patient management with on-site, on-call and online clinical support to ensure quality and help health care professionals achieve the best possible outcome for the patient.

Join our professional network to stay updated on our latest job openings, company news and Abiomed insights.

The Impella 2.5®, Impella CP® and Impella CP® with SmartAssist® Systems are temporary (≤ 6 hours) ventricular support devices indicated for use during high-risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease, when a heart team, including a cardiac surgeon, has determined high …

Abiomed provides on-site, on-call and online clinical support to help health care professionals achieve the best possible outcome for the patient.

疾患について 心疾患は、わが国の主な死因の第2位であり、 今なお増え続けています。 Impella は、心原性ショックなどの急性心不全や 慢性心不全急性増悪に適応します。